Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

Arrayit joins federal government to help control health care costs through early diagnosis of diseases

Arrayit Corporation is pleased to join the federal government in their efforts to help control health care costs through early diagnosis of diseases.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

4 Nov 2009

Arrayit Corporation joins federal government in their efforts to help control health care costs

Arrayit Corporation is pleased to join the federal government in their efforts to help control health care costs by leveraging Arrayit's leading edge health care platform.

2 Nov 2009

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

30 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

CAP commends SACGHS stand against human health-related gene patents

The College of American Pathologists today expressed its support for a key government advisory group's recommendation to create an exemption from liability for infringement of gene patent claims when used for patient care purposes.

24 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.

20 Oct 2009

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Arrayit joins federal government to help control health care costs through early diagnosis of diseases

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Breastfeeding: ADA position paper details health benefits for both infants and mothers

Arrayit Corporation joins federal government in their efforts to help control health care costs

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

CAP commends SACGHS stand against human health-related gene patents

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Early diagnostic for ovarian cancer to be developed

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

ImmunoCellular Therapeutics files a provisional patent application

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in